June 2016, Vol. 5, No. 5

← Back to Issue

Personalized Medicine in Oncology: Expanding Our Knowledge of Precision Medicine

Personalized Medicine in Oncology: Expanding Our Knowledge of Precision Medicine

Letter to Our Readers

Benson-pic-98pxDear Colleague,

This issue of Personalized Medicine in Oncology (PMO) is a testament to how far we’ve come in our understanding of, and novel approaches to, the treatment of cancer. Armed with knowledge of molecular biomarkers, genetic mutations, genomics, immunotherapeutics, and targeted therapies, we are better able to treat patients with cancer to obtain longer survival and higher quality of life than ever before.

This month, Christos Fountzilas, MD, and Virginia G. Kaklamani, MD, DSc, provide a review of BRAF mutations and implications when considering treatment strategies for patients with this mutation.

In our Interview with the Innovators department, we talk with Chief Scientific Officer Paul W. Dempsey, PhD, and Chief Medical Officer Paul Y. Song, MD, of Cynvenio about their multiple-template strategy that analyzes DNA from circulating tumor cells, circulating cell-free DNA in blood, and tissue biopsies, as well as the initiation of their clinical trial in triple-negative breast cancer. We hope you find our exchange insightful and helpful.

Is there a topic you would like to see discussed in PMO? An innovator in the oncology community you’d like to have interviewed? Please contact us with your comments and request at editorial@the-lynx-group.com.

As always, thank you for your loyal readership. It is our pleasure to serve you in your quest to provide personalized medicine to your patients.

Sincerely,

Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology

BRAF Mutations - June 16, 2016

Implications of BRAF Mutations in Cancer

Christos Fountzilas, MD; Virginia G. Kaklamani, MD, DSc
Department of Medicine, Division of Hematology/Oncology, Cancer Treatment Research Center,
The University of Texas Health Science Center at San Antonio, TX

Sustaining proliferative signaling is one of the hallmarks of cancer as described by Hanahan and Weinberg.1,2 Signals from multiple receptor tyrosine kinases converge to the mitogen-activated protein kinase (MAPK) signal transduction pathway and regulate multiple aspects of cell biology (Figure).3 Guanine triphosphate–binding proteins of the RAS family and regulators of [ Read More ]

American Association for Cancer Research - June 16, 2016

Pembrolizumab Elicits Response in Patients with Merkel Cell Carcinoma

Immunotherapy with the programmed death 1 (PD-1) inhibitor pembrolizumab induced durable responses in a phase 2 clinical trial of a virus-related cancer. Among 26 patients with Merkel cell carcinoma (MCC) treated in the trial, 12 of 14 patients (86%) who responded to pembrolizumab have ongoing responses after a median follow-up [ Read More ]